Bristol-Myers Squibb

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

Bristol-Myers Squibb to acquire IFM Therapeutics

Wednesday, August 9, 2017

Bristol-Myers Squibb and IFM Therapeutics (IFM) announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

[Read More]

Vaxil BioTherapeutics appoints Dr. Terry Plasse chief medical officer

Tuesday, July 25, 2017

Vaxil Bio, an Israeli-Canadian biotech developing innovative immunotherapy treatments for cancer, announced the appointment of Dr. Terry Plasse as its chief medical officer, responsible for the company’s clinical program surrounding its drug candidate, ImMucin. Dr. Plasse brings 30 years of clinical development experience, including advancing products from IND through to commercially marketed treatments for several big-pharma companies.

[Read More]

Bristol-Myers Squibb, QIAGEN ink NGS technology agreement

Monday, June 5, 2017

Bristol-Myers Squibb and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer treatment. This will leverage the combination of Bristol-Myers Squibb’s portfolio of I-O therapies with QIAGEN’s proven track record in developing and commercializing companion and complementary diagnostics as well as QIAGEN’s portfolio of NGS technologies. I-O therapies offer a novel way to treat cancer by using drugs to target the body’s immune system to help fight cancer.

[Read More]

Bavarian Nordic initiates phase II PROSTVAC combo prostate cancer trial

Wednesday, April 19, 2017

Bavarian Nordic initiated a phase II clinical trial of its prostate cancer immunotherapy candidate, PROSTVAC (rilimogene), in combination treatment with YERVOY (ipilimumab) and/or OPDIVO (nivolumab), both of which are immune checkpoint inhibitors from Bristol-Myers Squibb, as neoadjuvant therapy in patients with localized prostate cancer.

A lead-in stage will evaluate the safety of the combination of all three drugs in 10 patients with castration-resistant prostate cancer, followed by enrollment of up to 55 patients with localized prostate cancer in three cohorts, who will receive PROSTVAC in combination with either ipilimumab or nivolumab, or a combination of all three drugs prior to undergoing radical prostatectomy. The primary endpoint of the study is to evaluate and compare changes in T cell infiltration in the tumor after neoadjuvant treatment across the three different cohorts.

The principal investigator of the study is James L. Gulley, MD, Senior Investigator, Center for Cancer Research, part of the National Cancer Institute (NCI), and the sponsor of the study.  

“There are now 11 ongoing studies of PROSTVAC across various stages of prostate cancer. In recent years, there has been a growing interest in the evaluation of the immunotherapy candidate in earlier disease stages, where the cancer has not yet spread beyond the prostate. We are excited to learn more about the potential of PROSTVAC for treating this population, and to evaluate the potential synergistic effects of combining the vaccine with checkpoint inhibitors, as we believe PROSTVAC may enhance the clinical activity of these drugs,” said Paul Chaplin, president & chief executive officer of Bavarian Nordic.

This is the second trial conducted in collaboration with Bristol-Myers Squibb. The first trial was initiated in October 2016, and is investigating the combination treatment of PROSTVAC and ipilimumab at the University of California, San Francisco (UCSF), also in a neoadjuvant setting.

Medidata to acquire Mytrus

Tuesday, April 18, 2017

Medidata, a global provider of cloud-based solutions and data analytics for clinical research, has agreed to acquire Mytrus, an eClinical technology company specializing in patient-centered electronic informed consent (eConsent) and virtual trials.

[Read More]

Bristol-Myers Squibb, Nordic Bioscience collaborate on fibrosis biomarker technology

Tuesday, April 18, 2017

Bristol-Myers Squibb and Nordic Bioscience, a Danish company specializing in biomarker technologies, announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over 25 years’ experience in biomarker development and clinical trials with extensive expertise in rheumatology and fibrosis. A biomarker is a molecule that may be used to diagnose a disease, or predict disease progression and indicate response to therapy.

[Read More]

Parker Institute, Bristol-Myers Squibb, Cancer Research Institute collaborate

Wednesday, March 29, 2017

The Parker Institute for Cancer ImmunotherapyBristol-Myers Squibb and the Cancer Research Institute (CRI) have announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely with Parker Institute and CRI scientists and researchers, soliciting clinical research proposals from their networks and coordinating multi-site collaboration clinical studies to pursue some of the most difficult questions in cancer research. It will provide scientists with an ecosystem of advanced translational tools, precision immunotherapy and cutting-edge bioanalytical expertise to maximize learning and ensure the generation of high quality data to inform future development.

[Read More]